跳至主要内容
临床试验/NCT03108768
NCT03108768已完成不适用

Quality Control of CE-Certified Phonak Hearing Aids - 2016_37

Sonova AG1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2017年4月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Sonova AG
入组人数
20
试验地点
1
主要终点
Speech intelligibility in noise as signal to noise ratio in dB (dB SNR)

研究概览

简要总结

A methodical evaluation of new CE-labelled Phonak Hearing Systems is intended to be conducted on hard of participants with a hearing loss to grant quality control prior to product launch. The aim of the investigation series is to ensure zero-defect overall performance of the new hearing systems as well as maximum benefit for the participant with the devices in comparison to previously outstanding Phonak Hearing Systems.

详细描述

Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials in the way as planned for this study ("phase of final inspection"). This will be a controlled, single blinded and randomised active comparator clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adult hearing impaired persons (minimum age: 18 years) with and without (experience with) hearing aids
  • •Good written and spoken (Swiss) German language skills
  • •Healthy outer ear
  • •Ability to fill in a questionnaire (p/eCRF) conscientiously
  • •Informed Consent as documented by signature

排除标准

  • •Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product
  • •Limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland)
  • •Limited ability to describe listening impressions/experiences and the use of the hearing aid
  • •Inability to produce a reliable hearing test result
  • •Massively limited dexterity
  • •Known psychological problems
  • •Central hearing disorders

研究组 & 干预措施

Successor of Phonak Virto V

Experimental

The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.

干预措施: Hearing Aid (Successor of Phonak Virto V) (Device)

Phonak Virto V

Active Comparator

Phonak Virto V will be fitted to the participants individual hearing loss.

干预措施: Hearing Aid (Phonak Virto V) (Device)

结局指标

主要结局

Speech intelligibility in noise as signal to noise ratio in dB (dB SNR)

时间窗: Three weeks

The data, serving as primary outcomes are collected in a series of lab appointments. The speech intelligibility in noise will be assessed with the aid of the german Oldenburg sentence test. The result is the signal to noise ratio in dB (dB SNR). Descriptive statistics will be executed in the form of determining the median and quartiles. Interference statistics will be executed by applying the appropriate parametric or non-parametric test, depending on the data's distribution. A significance level of 5% is pursued.

次要结局

  • Speech intelligibility in percent in a quiet listening situation(One week)
  • Zero-defect performance in daily life(Three weeks)

研究者

发起方
Sonova AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验